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The Combination of Early and Rapid Type I IFN, IL-1a,
and IL-1b Production Are Essential Mediators of RNA-Like
Adjuvant Driven CD4+ Th1 Responses
Rachel F. Madera, Jennifer P. Wang, Daniel H. Libraty*
Division of Infectious Disease and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
There is a growing need for novel vaccine adjuvants that can provide safe and potent T-helper type 1 (Th1) activity. RNA-like
immune response modifiers (IRMs) are candidate T-cell adjuvants that skew acquired immune responses towards a Th1
phenotype. We set out to delineate the essential signaling pathways by which the RNA-like IRMs, resiquimod (R-848) and
polyinosinic:polycytidylic acid (poly I:C), augment CD4+ T-helper 1 (Th1) responses. Highly purified murine conventional
dendritic cells (cDCs) and conventional CD4+ T-cells were co-cultured in allogeneic and MHC congenic mixed leukocyte
reactions. The activation of CD4+ Th1 cells was examined utilizing cells from mice deficient in specific RNA-sensing pattern
recognition receptors and signaling mediators. R-848 and poly I:C stimulation of Type I interferon production and signaling
in cDCs was essential but not sufficient for driving CD4+ Th1 responses. The early and rapid production of IL-1a and IL-1b
was equally critical for the optimal activation of Th1 CD4+ T-cells. R-848 activation of Toll-like receptor 7/MyD88-dependent
signaling in cDCs led to a rapid upregulation of pro-IL-1a and pro-IL-1b production compared to poly I:C activation of
MyD88-independent signaling pathways. The in vitro data show that CD4+ T-cell adjuvant activity of RNA-like IRMs is
mediated by a critical combination of early and rapid Type I interferon, IL-1a and IL-1b production. These results provide
important insights into the key signaling pathways responsible for RNA-like IRM CD4+ Th1 activation. A better
understanding of the critical signaling pathways by which RNA-like IRMs stimulate CD4+ Th1 responses is relevant to the
rational design of improved vaccine adjuvants.
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Introduction
Adjuvants are important in eliciting robust protective immune
responses from vaccines but many of their underlying mechanisms
are yet to be fully elucidated [1]. Vaccine adjuvants mainly target
professional antigen-presenting cells (APCs) such as dendritic cells
and activate innate immunity through pattern recognition
receptor (PRR) pathways [1,2]. For protection against most
viruses and intracellular pathogens, adjuvants that stimulate CD4+
T helper type 1 (Th1) responses are desirable. CD4+ T-cell help is
known to be required for optimizing B-cell and CD8+ T-cell
responses, and can also provide protection through direct
cytotoxic effector functions [3,4]. Unfortunately, potent CD4+
T-cell adjuvant activity in humans has often been associated with
unacceptable toxicity (e.g. complete Freund’s adjuvant [5]).
Therefore, one of the major challenges in adjuvant research has
been to gain CD4+ Th1 stimulatory activity while minimizing
potential toxicity.
RNA-like immune response modifiers (IRMs) can skew acquired
immune responses towards a Th1 phenotype while suppressing Th2
responses [6,7,8,9]. Among these RNA-like IRMs, resiquimod (R-
848) and polyinosinic:polycytidylic acid (poly I:C) are being
evaluated as T-cell adjuvants for vaccine development
[7,10,11,12]. R-848 is a synthetic imidazoquinoline-like molecule
that triggers cellular responses via the endosomal Toll-like receptors
(TLRs) 7 and 8 and MyD88-dependent signaling [13,14]. Poly I:C
is a synthetic analog of viral dsRNA that activates MyD88-
independent immune responses through TLR3/TIR-domain-
containing adapter-inducing interferon-b (TRIF) and the melano-
ma differentiation associated protein 5 (MDA5)/Interferon-b
promoter stimulator 1 (IPS-1) signaling pathways [15,16].
These RNA-sensing PRRs and signaling pathways are present
in APCs and CD4+ T-cells [17,18]. RNA-like IRM activation of
MyD88-dependent and MyD88-independent signaling pathways
can induce a broad range of cell-specific responses, including NF-
kB activation, type I interferon (IFN) and pro-inflammatory
cytokine production, and co-stimulatory molecule upregulation
[6,9,17]. The ability of RNA-like adjuvants to stimulate CD4+
Th1 responses likely depends on a combination of key signaling
pathways in APCs and CD4+ T-cells. A better understanding of
the critical signaling pathways by which RNA-like IRMs stimulate
CD4+ Th1 responses will help in the establishment of effective
strategies in the generation of rationally designed vaccine
adjuvants.
In this paper, we set out to delineate the essential signaling
pathways by which the RNA-like IRMs, R-848 and poly I:C,
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augment CD4+ Th1 responses. Highly purified conventional
dendritic cells (cDCs) and conventional CD4+ T-cells were co-
cultured in mixed leukocyte reactions (MLRs) in order to evaluate
the specific RNA-like adjuvant effects on these central mediators
of primary immune responses. We found that R-848 was a more
effective CD4+ Th1 adjuvant than poly I:C in isolated cDC/
CD4+ T--cell interactions. Type I IFN production and Type I IFN
receptor signaling in cDCs were necessary but not sufficient for the
CD4+ T-cell adjuvant activity of the R-848. Early and rapid IL-1a
production and IL-1b secretion from cDCs were also necessary for
the CD4+ Th1 adjuvant properties of R-848. Moreover, addition
and blocking of these essential cytokines affect RNA-like IRM
stimulated CD4+ Th1 responses. Our results provide important
insights into the key signaling pathways responsible for RNA-like
IRM CD4+ T-cell activation, and will help in the rational design
of improved vaccine adjuvants.
Materials and Methods
Reagents
Resiquimod (R-848) was purchased from 3 M Pharmaceuticals
(St. Paul, MN) and poly I:C was purchased from Alexis
Biochemicals (San Diego, CA). Purified FITC-anti-mouse
CD11c, PE-anti-mouse CD11b, PerCP-anti-mouse-CD45R,
FITC-anti-mouse CD4, PerCPCy5.5-anti-mouse CD4,
PerCPCy5.5-anti-mouse CD8, PE-anti-mouse TCRb, Alexa
700-anti-mouse tumor necrosis factor-a (TNF-a) and Allophyco-
cyanin-anti-mouse IFN-c were purchased from BD Biosciences
(San Jose, CA). Purified Pacific Blue-anti-mouse CD3, and PE-
Cy7-anti-mouse DX5 were purchased from eBiosciences (San
Diego, CA). For the add-in and blocking experiments, the
following reagents were used: universal Type I IFN (PBL
Biomedical Laboratories, Piscataway, NJ), mouse rIL-1a, rIL-1b
and soluble IL-1 receptor antagonist (sIL-1Ra) (R & D Systems,
Minneapolis, MN), AnakinraTM (sIL-1R antagonist) (Amgen,
Thousand Oaks, CA), anti-mouse IFN a/b receptor IgG1 (anti-
IFNAR) (Leinco, St. Louis, MO), and purified mouse IgG1 isotype
control (BD Biosciences).
Mice
C57BL/6J (B6), BALB/cJ and B6.C-H2d/bByJ (B6.H2d) mice
were purchased from The Jackson Laboratory (Maine, USA).
MyD882/2, TLR72/2, IL-1R2/2 and type I IFN receptor2/2
(IFNAR2/2) mice were provided by Drs. R. Finberg and K.
Fitzgerald (University of Massachusetts Medical School, Worces-
ter, MA) [19,20,21]. IL-1a2/2, IL-1b2/2 and IL-1ab2/2 mice
were provided by Drs. K. Rock and H. Kono (University of
Massachusetts Medical School) [22,23]. The genetically modified
knockout mice were backcrossed eight or more generations onto
the B6 background and were then intercrossed to obtain the
knockout genotypes. All animal procedures were conducted in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the University of
Massachusetts Medical School Animal Care and Use Committee
(Protocol A-1884).
cDCs and CD4+ T cells
Bone-marrow derived dendritic cells were prepared as
described previously [24]. In brief, bone marrow cells were
cultured in RPMI supplemented with 10% FBS, 50 mM 2-
mercaptoethanol and 20 ng/ml recombinant fms-related tyrosine
kinase 3 ligand (rFlt3L, R&D Systems) for 7 days. Bone-marrow
derived dendritic cells were scraped off the culture dish, washed
with PBS and then stained with fluorochrome-conjugated
antibodies for fluorescence-activated cell sorting (FACS). cDCs
(CD11c+CD11b+CD45R2/lo) were isolated by sorting on a BD
FACSAria flow cytometer (BD Biosciences). Conventional CD4+
T-cells were isolated from mice splenocytes by magnetic bead
enrichment for CD4+ T-cells (MACS, Miltenyi Biotec, Auburn,
CA) followed by flow cytometry sorting for the
CD3+CD4+CD82DX52TCRb+ lymphocytes. Analysis of the
cDC and CD4+ T-cells after FACS consistently demonstrated
$99% purity. The sorted CD4+ T-cells were at least 80%
CD62Lhi indicating mostly naı¨ve CD4+ T-cells. Cell culture
supernatants and cellular RNA were collected at the indicated
time points for ELISA and RT-PCR analyses.
Mixed Leukocyte Reactions, (MLR)
FACS-sorted cDCs and CD4+ T cells were co-cultured for six
days in allogeneic and MHC congenic MLRs. Initial experiments
were done using cells from wild-type B6 (H2b) and BALB/c (H2d)
mice to have an allogeneic response, and subsequently switched
to using MHC congenic H2d mice on the B6 background, B6.C-
H2d/bByJ (B6.H2d). No apparent differences between the
allogeneic or MHC congenic systems were observed. The
murine TLR7 agonist, R-848, and the TLR3 and MDA5
agonist, poly I:C, were added to MLRs at final concentrations of
20 mM and 100 mg/ml, respectively. These agonist concentra-
tions produced maximal T-cell responses in preliminary
experiments. After six days, cell-free culture supernatants were
collected for ELISA and cells were collected for intracellular
cytokine staining (ICS).
Intracellular cytokine staining
IFN-c and TNF-a-secreting CD4+ T-cells were quantified by
ICS assay. Briefly, cells from MLRs were washed with media then
cultured for 5 to 6 hours without restimulation in the presence of
Brefeldin A (BD Biosciences, San Jose, CA). Cells were stained
with surface antibodies, and permeabilized with Cytofix/Cyto-
perm (BD Biosciences, San Jose, CA) before intracellular staining
with antibodies and fixation. CD4+ T-cells were analyzed using a
BD FACSAria cytometer. LIVE/DEADH Fixable Dead Cell Stain
Kit (Invitrogen, Carlsbad, CA) was used to exclude nonviable cells
from analysis.
ELISA
Cell culture supernatants were collected and analyzed for mouse
IFN-c, IL-1a and IL-1b by ELISA according to the manufactur-
er’s protocol (BD Biosciences, San Jose, CA). The ELISA plates
were developed using 3,39,5,59-tetramethylbenzidine (KPL, Gai-
thersburg, MD), and the reactions were stopped with 2N sulfuric
acid. Optical densities were read at 450 nm using a Spectra MAX
microplate reader and analyzed with SoftmaxH Pro 5 Software
(Molecular Devices, Sunnyvale, CA).
Quantitative RT-PCR
IL-1a, IL-1b and IFN-b mRNA expression were determined
using RNeasy Plus Mini Kit for RNA extraction (Qiagen,
Valencia, CA) and TaqMan RNA-to-CT 1-step kit for RT-PCR
(Applied Biosystems, Carlsbad, CA). All primers and probes used
were TaqMan Pre-Developed Assay Reagents for Gene Expres-
sion (Applied Biosystems, Carlsbad, CA). Levels of gene expression
were normalized to b-actin for each sample. Fold increase in gene
expression was determined using the DDCT method. Samples were
Type I IFN and IL-1 Essential for T-Cell Adjuvants
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run in triplicates and the results are presented as linear-fold
changes in gene expression.
Addition of IL-1 and blockade of type I IFN and IL-1a/b
signaling
Poly I:C stimulated MHC congenic MLRs had mouse rIL-1a
and rIL-1b (125 pg/ml each) added. To block endogenous type I
IFN and IL-1 signaling, anti-mouse IFN a/b receptor IgG1 (5 mg/
ml) and AnakinraTM (10 mg/ml) or recombinant mouse sIL-1Ra
(1 mg/ml) were added to R-848 stimulated MHC congenic MLRs.
Purified mouse IgG1 isotype antibody (5 mg/ml) was used as a
control. After six days, cell-free culture supernatants were collected
for ELISA and cells were collected for ICS, as previously
described.
Statistical analysis
Statistical analysis was done using GraphPad Prism Software
version 5.00 (GraphPad, San Diego, CA). Comparisons between
two groups were performed using paired or unpaired Student’s t-
test, as appropriate. Comparisons among .2 groups were
performed using analysis-of-variance (ANOVA). A difference
was considered significant if the p-value was ,0.05.
Results
R-848.poly I:C augmented alloreactive CD4+ Th1
responses in a cDC/CD4+ T-cell MLR
We utilized a MHC congenic MLR to investigate the essential
signaling pathways by which RNA-like IRMs stimulate CD4+ Th1
responses. Highly purified murine cDCs and highly purified MHC
congenic conventional CD4+ T-cells were co-cultured for six days
in the presence or absence of RNA-like IRMs. The cDCs and
CD4+ T-cells were sorted by flow cytometry to high purity in
order to eliminate the potential effects of bystander cells (e.g.
natural killer cells, cd T-cells). Alloreactive CD4+ T-cell cytokine
production was measured in cell culture supernatants and by ICS.
At maximal doses, the murine TLR7 agonist R-848 was a strong
stimulator of alloreactive IFN-c-producing CD4+ T-cells; whereas,
the TLR3 and MDA5 agonist poly I:C was less potent in this
system (Figures 1A&B). Nearly all R-848 or poly I:C induced IFN-
c+ CD4+ T-cells also produced TNF-a (Figure 1B) and IL-2 (data
not shown). From here on, RNA-like IRM augmentation of CD4+
Th1 responses are reported as IFN-c expression and production.
The data indicated that RNA-like IRM activation of MyD88-
dependent signaling pathways (R-848) stimulated CD4+ Th1
Figure 1. R-848.poly I:C induces IFN-c+ and TNF-a+ alloreactive CD4+ T-cells in a MLR. Highly purified bone-marrow derived
conventional dendritic cells (cDCs)(CD11c+CD11b+CD45R2/lo) and conventional CD4+ T-cells (CD3+ CD4+CD82TCRb+DX52) were co-cultured for 6 d
in the presence or absence of RNA-like IRMs. (A) Cell culture supernatant IFN-c levels. Values are mean6 SEM (n= 3), **R-848 p,0.0001 compared to
media control; *poly I:C p= 0.0343 compared to media control. (B) ICS staining for IFN-c and TNF-a producing conventional CD4+ T-cells
(representative of three independent experiments shown). Values shown are the % of CD3+CD4+ T-cells producing IFN-c (left column) and % IFN-
c+TNF-a2, IFN-c2TNF-a+, or IFN-c+TNF-a+ (right column).
doi:10.1371/journal.pone.0029412.g001
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responses better than MyD88-independent signaling pathways
(poly I:C) in isolated cDC/CD4+ T-cell interactions.
Type I IFN signaling in cDCs was necessary for RNA-like
IRMs to stimulate CD4+ Th1 responses in a cDC/CD4+ T-
cell MLR
RNA-like IRMs and RNA-sensing PRRs induce Type I IFN
production and signaling in cDCs [7,11], and Type I IFN can
drive DC maturation and activation [25]. R-848 stimulated
alloreactive CD4+ T-cell IFN-c responses were abolished in
IFNAR2/2 cDC/B6.H2d CD4+ T-cell MLR compared to wild-
type B6 cDC/B6.H2d CD4+ T-cell MLR (Figures 2A&B). The
small increase in alloreactive CD4+ T-cell IFN-c responses
induced by poly I:C was also abrogated when utilizing
IFNAR2/2 cDCs. Type I IFN signaling in cDCs was essential
for the ability of R-848 and poly I:C to augment alloreactive
CD4+ T-cell IFN-c production in isolated cDC/CD4+ T-cell
interactions. However, R-848 induced much lower IFN-b mRNA
levels in cDCs compared to poly I:C (Figure 2C), and yet
stimulated much higher CD4+ T-cell IFN-c responses compared
to poly I:C. This suggested that Type I IFN production and
signaling in cDCs was essential but not sufficient for optimal RNA-
like IRM stimulation of CD4+ Th1 responses.
R-848 stimulation of CD4+ Th1 responses was dependent
on MyD88-mediated signaling in cDCs and conventional
CD4+ T-cells
R-848 activates murine TLR7/MyD88-dependent signaling
[26] and R-848 has been reported to have direct effects on
cDCs and CD4+ T-cells [18,27,28]. We therefore examined the
role of MyD88-dependent signaling pathways in cDCs and CD4+
T-cells during R-848 stimulation of alloreactive CD4+ Th1
responses. Not surprisingly, R-848-induced alloreactive CD4+ T-
cell IFN-c production was entirely abrogated when MyD882/2
or TLR72/2 cDCs were used in MHC congenic MLRs
(Figure 3A). However, R-848-induced alloreactive CD4+ T-cell
Figure 2. Type I IFN is essential for RNA-like IRMs to stimulate CD4+ Th1 responses in a cDC/CD4+ T-cell MLR. (A) IFN-c levels in cell
culture supernatants in MHC congenic MLRs utilizing B6 or IFNAR2/2 cDCs. Values are mean 6 SEM (n= 3). ** p= 0.0008 compared to R-848
stimulated B6 cDC MLR, * p = 0.0037 compared to poly I:C stimulated B6 cDC MLR. (B) ICS staining for IFN-c producing conventional CD3+CD4+ T-cells
in MHC congenic MLRs utilizing B6 or IFNAR2/2 cDCs (representative of three independent experiments shown). Values shown are the % of IFN-c+
conventional CD3+CD4+ T-cells. (C) cDCs were stimulated with R-848, poly I:C, or media (unstimulated control), and cellular RNA was collected at the
indicated time points. IFN-bmRNA levels were measured by qRT-PCR, as described in the Methods section. Bars represent fold-change in IFN-bmRNA
relative to unstimulated control at the 6 h time point (mean 6 SEM, n = 3).
doi:10.1371/journal.pone.0029412.g002
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IFN-c production was also fully abrogated when MyD882/2
conventional CD4+ T-cells were used in MLRs. This MyD88-
dependence in conventional CD4+ T-cells was not mediated
through TLR7 or IL-18 receptor signaling (Figure 3B and data
not shown). The data indicated that R-848 activation of
TLR7/MyD88-dependent signaling in cDCs was critical for
augmenting alloreactive CD4+ Th1 responses, and that TLR7-
independent/MyD88-dependent signaling in CD4+ T-cells was
equally critical.
cDC IL-1a and IL-1b production, and IL-1R-mediated
signaling in cDCs and conventional CD4+ T-cells, were
essential for R-848 stimulation of CD4+ Th1 responses
We next explored the role of IL-1R/MyD88 signaling in R-
848 stimulation of CD4+ Th1 responses. When IL-1R2/2 cDCs
were used in the MHC congenic MLRs, R-848-induced
alloreactive CD4+ T-cell IFN-c production was 4569% lower
than when wild-type cDCs were used (mean6SEM, n = 3,
p = 0.03). Similarly, when IL-1R2/2 CD4+ T-cells were used
in MHC congenic MLRs, R-848-induced alloreactive CD4+ T-
cell IFN-c production was 5565% lower than wild-type CD4+
T-cells (mean6SEM, n = 3, p = 0.01). The observed effect of IL-
1R-mediated signaling on R-848 stimulation of CD4+ Th1
responses in both cDC and CD4+ T-cells prompted us to
examine the roles of cDC IL-1a and IL-1b production. R-848-
induced alloreactive CD4+ T-cell IFN-c production was nearly
completely abrogated when IL-1a2/2, IL-1b2/2, or IL-1ab2/2
cDCs were used in the MLRs (Figures 4A&B). IL-1a and IL-1b
had largely non-redundant roles in driving the alloreactive CD4+
Th1 responses to R-848 in this system. Collectively, our data
suggest that the combination of Type I IFN, IL-1a, and IL-1b are
necessary for the optimal stimulation of CD4+ Th1 responses by
RNA-like IRMs.
R-848 rapidly increases cDC production of pro-IL-1a and
pro-IL-1b mRNA and protein
R-848 stimulation of cDCs produced a rapid upregulation of
pro-IL-1a and pro-IL-1b mRNA (Figures 5A&B); whereas, poly
I:C stimulation of cDCs produced a slower and more gradual
increase in pro-IL-1a and pro-IL-1b mRNA expression
(Figures 5C&D). Biologically active IL-1a (precursor and mature
IL-1a) is primarily intracellular and membrane-associated, while
biologically active IL-1a (mature IL-1b) is primarily secreted [29].
Comparable levels of IL-1a protein (precursor and mature forms)
were measured in the cell lysates from R-848 and poly I:C-
stimulated cDCs at early time points (data not shown). R-848 and
extracellular ATP stimulation of cDCs rapidly induced higher
levels of secreted mature IL-1b protein in cell-free culture
supernatants compared to poly I:C and extracellular ATP
(Figures 5E&F, Figure S1).
When 200 U/ml type I IFN and 125 pg/ml each of rIL-1a and
rIL-1b were added to a MHC congenic cDC/CD4+ MLR, type I
IFN and IL-1 were sufficient to induce a three-fold increase in
alloreactive CD4+ T-cell IFN-c production and was comparable
to poly I:C but not R-848 (data not shown). Poly I:C induced rapid
and sustained Type I IFN production (Figure 2C), but induced
pro-IL-1a and pro-IL-1b at later time points compared to R-848
(Figure 5). To further examine the early roles of IL-1a and IL-1b,
Figure 3. TLR7 signaling in cDCs, and TLR7-independent/MyD88-mediated signaling in CD4+ T-cells, are essential for R-848
induced CD4+ Th1 responses. (A) ICS staining for IFN-c producing CD4+ T-cells in MHC congenic MLRs utilizing B6, MyD882/2, or TLR72/2 cDCs
(representative of two independent experiment shown) (B) ICS staining for IFN-c producing CD4+ T-cells in MHC congenic MLRs utilizing B6,
MyD882/2, or TLR72/2 CD4+ T-cells (representative of two independent experiments shown). Values shown are the % of IFN-c+ conventional
CD3+CD4+ T-cells.
doi:10.1371/journal.pone.0029412.g003
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we added mouse rIL-1a and rIL-1b at the same time as poly I:C in
MHC congenic MLRs. Addition of IL-1a and IL-1b increased
poly I:C induced cytokine-producing (IFN-c, TNF-a and IL-2)
CD4+ T-cells (Figure 6). The data indicated that early IL-1a and
IL-1b production and signaling are essential for the robust RNA-
like IRM (poly I:C and R-848) stimulation of CD4+ Th1
responses.
Inhibition of IL-1 and Type I IFN signaling abrogated R-
848 stimulation of CD4+ Th1 responses
To further assess R-848-induced CD4+ Th1 responses, a
natural inhibitor of IL-1 signaling, sIL-1Ra, and its synthetic form,
AnakinraTM, were added to R-848 stimulated MHC congenic
MLRs. To inhibit Type I IFN signaling, antibodies against the
IFN a/b receptor were also added. Inhibition of both IL-1 and
Type I IFN signaling diminished the robust R-848 induced CD4+
Th1 responses (Figure 7). Inhibition of either IL-1 or Type I IFN
signaling also reduced R-848 induced CD4+ Th1 responses but to
a lesser degree (Figure 7). Taken together, Type I IFN production
and signaling by itself was not sufficient to drive RNA-like IRM
stimulated CD4+ Th1 responses. The combined actions of Type I
IFN, IL-1a, and IL-1b were essential for the optimal activation of
alloreactive CD4+ Th1 responses in cDC/conventional CD4+ T-
cell interactions.
Discussion
There is a growing need for novel vaccine adjuvants with potent
T-cell immune stimulatory effects. In this paper, we investigated
the critical cellular signaling pathways used by RNA-like IRMs (R-
848 and poly I:C) to stimulate CD4+ Th1 responses during
alloreactive cDC/CD4+ T-cell interactions. RNA-like IRM
stimulation of Type I IFN production and signaling was essential
but not sufficient for driving CD4+ Th1 responses. The rapid and
early production of IL-1a and IL-1b was equally critical for the
optimal activation of Th1 CD4+ T-cells. In cDCs, R-848
activation of TLR7/MyD88-dependent signaling led to a rapid
upregulation of pro-IL-1a and pro-IL-1b production compared to
poly I:C activation of MyD88-independent signaling pathways. R-
848 stimulated the early production and secretion of mature IL-1b
from cDCs and augmented alloreactive CD4+ Th1 responses to a
greater degree than poly I:C. Our data suggests that the CD4+ T-
cell adjuvant activity of RNA-like IRMs is mediated by a critical
combination of rapid Type I IFN, IL-1a and mature IL-1b
production.
The RNA-like IRMs, R-848 and poly I:C, are well-known
inducers of Type I IFN in many cell types and have been shown to
be potent CD4+ T-cell adjuvants [8,11,12,30]. Longhi et al. [7]
primed and boosted mice with a dendritic cell targeted HIV gag
Figure 4. IL- 1a and IL-1b are essential for R-848 stimulation of CD4+ Th1 responses. (A) Cell culture supernatant IFN-c levels (day 6) in
MHC congenic MLRs utilizing B6, IL-1a2/2, IL-1b2/2 or IL-1ab2/2 cDCs. Values are mean 6 SEM (n= 2). *p,0.05 compared to R-848 stimulated B6
cDC MLR. (B) ICS staining for IFN-c producing CD4+ T-cells in MHC congenic MLRs utilizing B6, IL-1a2/2, IL-1b2/2 or IL-1ab2/2 cDCs (representative of
two independent experiments shown). Values shown are the % of IFN-c+ conventional CD3+CD4+ T-cells.
doi:10.1371/journal.pone.0029412.g004
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protein vaccine and TLR agonists. They found poly I:C to be the
most effective inducer of Type I IFN and the superior adjuvant to
elicit CD4+ T cell immunity. Antibody blocking or deletion of
Type I IFN receptor markedly reduced DC maturation, T-cell
proliferation, and the development of adaptive Th1 immunity in
response to the HIV gag protein. Ichinohe et al. [31] also
investigated the mucosal adjuvant effect of poly I:C by intranasal
co-administration with inactivated influenza virus HA vaccines
and observed cross-protection against heterologous infection. The
authors observed upregulated expression of Type I IFN, and Th1/
Th2 cytokines following the administration of HA vaccine with
poly I:C. Vasilakos et al. [8] demonstrated that mice immunized
with chicken ovalbumin and R-848 induced high levels of Type I
IFN, and neutralizing antibodies to Type I IFN inhibited
ovalbumin-specific CD4+ Th1 responses. Similarly, in isolated
cDC/CD4+ T-cell interactions, we found that Type I IFN
production and signaling was necessary for the activation of Th1
alloreactive CD4+ T-cells by RNA-like IRMs. However, poly I:C
was a more potent inducer of Type I IFN in highly purified cDCs
compared to R-848, yet it was less potent at stimulating
alloreactive CD4+ Th1 responses. This suggested that Type I
IFN production and signaling in cDCs was indeed essential but not
sufficient for RNA-like IRMs to augment CD4+ Th1 responses in
isolated alloreactive cDC/CD4+ T-cell interactions.
We found that the ability of R-848 to augment alloreactive
CD4+ Th1 responses in a cDC/CD4+ T-cell MLR was also
dependent on the early and rapid production of functional IL-1a
and IL-1b from cDCs. MyD88-dependent IL-1R mediated
signaling in both cDCs and CD4+ T-cells was important in
mediating the CD4+ Th1 stimulatory effect of R-848. IL-1
stimulates cDC maturation and activation [32,33] and can act
directly on CD4+ T-cells to enhance their differentiation and
cytokine production [34].
The Th1 adjuvant effects of IL-1 have been previously reported
in in vivo studies. In the pigeon cytochrome C (PCC) adoptive
transfer studies of Ben-Sasson et al. [34], mice recipients were
immunized with PCC peptide together with proinflammatory
cytokines (administered through a miniosmotic pump). Among the
series of cytokines tested, including TNFa, IL-1, IL-6, IL-18 and
IL-33, only IL-1 augmented primary immune responses. IL-1a
and IL-1b displayed similar potency [34]. In addition to the IL-1
adjuvant effect during antigen priming, both the time and the
concentration of IL-1 administration are critical. Staruch et al.
[35] have shown that the maximum IL-1 adjuvant effect was
2 hours after the priming dose of bovine serum albumin (BSA)
protein antigen. These authors have also observed dose-dependent
enhancement of CD4+ T-cell responses to BSA. Similarly, in our
MHC congenic MLR system, we found that the early addition of
IL-1 conferred increased adjuvant effects of poly I:C.
The observed comparable decreases in IFN-c producing CD4+
T cells when utilizing IL-1a2/2, IL-1b2/2 and IL-1ab2/2 cDCs
in the MLRs suggested that IL-1a and IL-1b have largely non-
Figure 5. R-848 induces a rapid increase in pro-IL- 1a and pro-IL-1b mRNA expression and protein production in cDCs. cDCs were
stimulated with R-848, poly I:C, or media (unstimulated control), and cellular RNA and cell culture supernatants were collected at the indicated time
points. Pro-IL- 1a (A&B) and pro-IL-1b (C&D) mRNA levels were measured by qRT-PCR, as described in the Methods section. Bars represent fold-
change in pro-IL- 1a or pro-IL-1b mRNA relative to unstimulated control at the 6 h time point (mean 6 SEM, n = 3). (E&F) IL-1b protein levels
(precursor and mature forms) were measured in cell culture supernatants by ELISA (mean 6 SEM, n= 2).
doi:10.1371/journal.pone.0029412.g005
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redundant roles in stimulating alloreactive CD4+ Th1 responses.
Though IL-1a and IL-1b both bind and activate IL-1R [36],
differences in their localization might explain their apparent non-
redundant effects [29,37,38]. Biologically active IL-1a (precursor
and mature forms) is predominantly cell- and membrane-
associated, and likely acts in an autocrine or even intracrine
manner in antigen-presenting cells [29]. By contrast, pro-IL-1b is
biologically inactive and has different posttranslational processing
requirements than pro-IL-1a. Caspase-1-containing inflamma-
somes (e.g. NLRP3 inflammasome) cleave pro-IL-1b into the
biologically active mature form which is secreted into the
extracellular environment in a non-classical manner [37,39].
Thus, mature IL-1b likely acts predominantly in a paracrine or
endocrine manner, activating IL-1R signaling in effector cells such
as CD4+ T-cells. Other studies conducted on IL-1a and IL-1b-
deficient mice have also shown non-redundant roles for these
cytokines in immune responses and disease pathogenesis. IL-1b,
but not IL-1a, was required for antigen-specific T-cell activation in
delayed-type hypersensitivity responses [40] and in T-cell
dependent antibody production against sheep red blood cells
[41,42]. IL-1a, but not IL-1b, modulated the antiviral and
immunoregulatory activities of IFN-c [42], and was necessary for
cell- and tissue-injury induced sterile inflammatory responses [43].
Further studies are needed to discriminate the potential non-
redundant roles of IL-1a and IL-1b in the RNA-like adjuvant
augmentation of CD4+ Th1 responses.
In cDCs, R-848 induced less Type I IFN but early and more
robust IL-1a and IL-1b production than poly I:C. R-848 was also
Figure 6. The addition of rIL- 1a and rIL-1b increases poly I:C-induced CD4+ Th1 responses in a cDC/CD4+ T-cell MLR. (A) Cell culture
supernatant IFN-c levels in poly I:C stimulated MHC congenic MLR with mouse rIL- 1a and rIL-1b. ICS staining for IFN-c (B), TNF-a (C) and IL-2 (D)
producing conventional CD4+ T-cells. Values are mean6 SEM (n= 3) (representative of two independent experiments shown). *p,0.05 compared to
media control.
doi:10.1371/journal.pone.0029412.g006
Figure 7. Inhibition of Type I IFN, IL- 1a and IL-1b signaling
decreases R-848-induced CD4+ Th1 responses in a cDC/CD4+ T-
cell MLR. Cell culture supernatant IFN-c levels (day 6) in MHC congenic
MLRs with Type I IFN and IL-1 signaling blocked by anti-mouse IFN a/b
receptor, AnakinraTM and sIL-1Ra. Compared to a R-848 stimulated MHC
congenic MLR, decreased CD4+ Th1 responses were observed in MLRs
with blocked Type I IFN, IL-1a and IL- 1b signaling. Blocking of either
Type I IFN or IL-1a/b signaling also decreased cell culture supernatant
IFN-c levels. Values are mean 6 SEM (n= 6). *p,0.05 compared to R-
848 stimulated MLR.
doi:10.1371/journal.pone.0029412.g007
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a more potent CD4+ T-cell adjuvant compared to poly I:C in the
cDC/CD4+ T-cell MHC congenic MLR system. However, poly
I:C has also been shown to be a potent CD4+ T-cell adjuvant in
vivo [6,7,31]. When administered as an adjuvant in mice, the main
source of poly I:C-induced Type I IFN has been reported to be
non-hematopoietic cells [7]. In addition, poly I:C has been shown
to induce mRNA expression [44] and protein production of IL-1
both in vitro [45,46] and in vivo [45,47,48]. In our isolated cDC/
CD4+ T-cell MHC congenic MLR, poly I:C appears unable to
stimulate enough Type I IFN and IL-1. The increase in CD4+
Th1 responses with exogenous rIL-1 in poly I:C stimulated MHC
congenic MLRs supports this hypothesis. Furthermore, increased
Type I IFN production has been shown to inhibit IL-1 production
by inhibiting inflammasome function and inducing regulatory IL-
10 [49]. The delayed IL-1 production observed in poly I:C
stimulated MHC congenic MLRs may be an effect of the robust
poly I:C-induced type I IFN in the isolated cDC/CD4+ T-cell
MLR system. The essential roles of these cytokines were also
evident in the abrogation of CD4+ Th1 responses upon Type I
IFN and IL-1 signaling blockade in R-848 stimulated MHC
congenic MLRs. The observed differences in the cDC production
of type I IFN, IL-1a and IL-1b between R-848 and poly I:C
indicate complex signaling cascades for the initiation of CD4+
Th1 responses. Elucidation and a better understanding of these
mechanisms would offer further possibilities for the use of these
RNA-like IRMs as adjuvants.
Finally, we observed that the ability of R-848 to augment
alloreactive CD4+ Th1 responses was nearly completely depen-
dent on MyD88-mediated signaling in the CD4+ T-cells. IL-1R
mediated signaling could only explain part of this profound CD4+
T-cell MyD88 signaling dependence. The isolated removal of
CD4+ T-cell TLR7 or IL-18 receptor signaling did not affect R-
848 induced alloreactive CD4+ Th1 responses. It is possible that
there is overlap and a partial redundancy of the signaling effects in
CD4+ T-cells among IL-1R, IL-18R, and TLR7/MyD88
dependent pathways. It may also be possible that other MyD88-
dependent signaling pathways in CD4+ T-cells, yet to be
identified, are involved in priming and activation [50]. A better
understanding of the adjuvant mechanisms that promote CD4+
Th1 responses will be important for the rational design of new
vaccine strategies. RNA-like IRMs are effective CD4+ Th1
adjuvants and their ability to induce Type I IFN was previously
shown to be critical for their T-cell stimulatory activity. In MLRs
utilizing two specific cell types, cDCs and conventional CD4+ T-
cells, we have shown that early and rapid IL-1a and mature IL-1b
production are equally critical. Together, these results show that
the CD4+ T-cell adjuvant activity of RNA-like IRMs involves a
complex interplay of critical PRR and innate immune signaling
pathways in different cells.
Supporting Information
Figure S1 R-848 and extracellular ATP stimulates early
mature IL-1b secretion from cDCs. Non-primed DCs were
stimulated for 6 h with R-848 or poly I:C with extracellular ATP
(5 mM). As a positive control, cDCs were primed with
lipopolysaccharide (200 ng/ml) for 3 hours prior to stimulation
with nigericin (10 mM). Mature IL-1b protein was detected by
Western blot in cell culture supernatants. Data shown is
representative of three independent experiments.
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